NCT05980416 2025-11-14
Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2
Elevation Oncology
Phase 1 Terminated
Clinical Trials
10 trialsNCT02597036 2025-10-23
A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors
Eli Lilly and Company
Phase 1 Terminated
NCT05071053 2025-08-22
CARMEN-GC01
Sanofi
Phase 2 Terminated
NCT04394624 2025-06-06
CARMEN-LC04
Sanofi
Phase 2 Terminated
NCT05311176 2025-05-11
nextHERIZON
Imugene Limited
Phase 2 Terminated
NCT03502746 2024-05-14
Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma
Hoosier Cancer Research Network
Phase 2 Terminated
NCT04145700 2023-09-13
CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma
Eli Lilly and Company
Phase 1/2 Terminated
NCT04557384 2023-02-27
A Study of Ramucirumab (LY3009806) Given by Injection Under the Skin in Participants With Advanced Cancer
Eli Lilly and Company
Phase 1 Terminated
NCT03904108 2022-05-26
Platinum-Based Chemotherapy Plus Ramucirumab in Patients With Advanced NSCLC Who Have Progressed on First Line Anti-PD-1 Immunotherapy
Stony Brook University
Phase 2 Terminated
NCT02726399 2020-01-21
Phase II Study of Ramucirumab With Chemotherapy in Patients With Metastatic Gastroesophageal Junction and Gastric Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Terminated